| Primary information |
|---|
| ID | antitb_1881 |
| Peptide Name | Polydim-I |
| Sequence | AVAGEKLWLLPHLLKMLLTPTP |
| N-terminal Modification | Free |
| C-terminal Modification | Free |
| Chemical Modification | None |
| Linear/ Cyclic | Linear |
| Length | 22 |
| Chirality | L |
| Nature | Amphipathic |
| Source | Natural |
| Origin | Isolated from the venom of the Neotropical wasp Polybia dimorpha |
| Species | Mycobacterium abscessus |
| Strain | Mycobacterium abscessus subsp. massiliense isolates GO 01, GO 06, GO 07, GO 08, GO 13, and GO 18, CRM0020 (Mycobacterium abscessus subsp. massiliense), and ATCC19977 (Mycobacterium abscessus subsp. abscessus) |
| Inhibition Concentartion | MIC = 60.8 μg/mL |
| In vitro/In vivo | Both |
| Cell Line | Peritoneal macrophages, J774 macrophages cells, human red blood cells |
| Inhibition Concentartion | Treatment of infected macrophages with 7.6 μg/mL of Polydim-I decreased approximately 50% of the bacterial load |
| Cytotoxicity | Non-cytotoxic, 10% cytotoxicity on J774 cells at concentrations above 121.6 μg/mL (10%) and concentrations up to 121.6 μg/mL presented less than 2.5% of hemolytic activity |
| In vivo Model | 6 to 8 weeks old BALB/c and IFN-γKO (Knockout) female mice |
| Lethal Dose | 2 mg/kg/mLW shows 90% reduction in bacterial load |
| Immune Response | NA |
| Mechanism of Action | Cell wall disruption |
| Target | Cell wall |
| Combination Therapy | None |
| Other Activities | NA |
| Pubmed ID | 26930596 |
| Year of Publication | 2016 |
| 3-D Structure | NA |